Pharma Focus Europe

Yuhan Corporation and J INTS BIO Forge Licensing Agreement for Novel Drug Candidate Addressing HER2 in NSCLC

Wednesday, May 31, 2023

Yuhan Corporation, led by CEO Wook-Je Cho, announced on May 30th that it has entered into an in-license agreement with J INTS BIO, headed by CEO Anna Jo. The agreement involves the acquisition of a Tyrosine Kinase Inhibitor (TKI) known as 'JIN-A04,' which specifically targets HER2. The total value of the contract is $325 million, which includes an upfront payment of $1.9 million and milestone payments based on future development, permits, and sales.

JIN-A04 is an oral TKI designed to treat non-small cell lung cancer (NSCLC) with HER2 mutations. Currently, there are no approved oral drugs available for this indication. Promising preclinical data on JIN-A04 was recently presented at the 2023 American Cancer Research Association (AACR) annual meeting in April, demonstrating its efficacy in in-vitro and in-vivo studies.

Yuhan Corporation CEO Wook-Je Cho expressed the company's commitment to expanding its anti-cancer drug pipeline through this agreement, stating that it represents progress in the development of the 2nd and 3rd LECLAZA. Yuhan Corporation plans to strengthen its anticancer drug pipeline further in the future.

CEO Anna Jo of J INTS BIO highlighted the potential of JIN-A04 as a hope for NSCLC patients with 'HER2 Exon20 insertion' mutations. She expressed optimism that JIN-A04 could become a leading TKI therapy in this field.
In addition to the recent agreement, Yuhan Corporation had previously invested $1.5 million in J INTS BIO in both 2021 and 2022, and currently holds a 14.8% stake in the company.

https://www.prnewswire.com/news-releases/yuhan-corporation-and-j-ints-bio-inked-a-licensing-agreement-for-a-new-drug-candidate-targeting-her2-nsclc-301838147.html
 

magazine-slider-img
Thermo Fisher Scientific - mRNA ServicesWorld Orphan Drug Congress 2024World Vaccine Congress Europe 2024Advanced Therapies USA 2024
cytiva